Cognitive Function in Patients with Prostate Cancer on Luteinizing Hormone-Releasing Hormone Analogues: A Prospective Observational Multicentric Study

Publication date: Available online 6 March 2017
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Juan Morote, Ángel José Tabernero, José Luis Álvarez Ossorio, Juan Pablo Ciria, José Luis Domínguez-Escrig, Fernando Vázquez, Javier Angulo, Francisco J. López, Ramón de La Iglesia, Jesús Romero
PurposeThe effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in prostate cancer (PCa) patients is not well-understood. We evaluated changes in CP after 6 months of medical castration with luteinizing hormone-releasing hormone (LHRH) analogues.Material and MethodsProspective, observational, multicentre, open-label study of PCa patients scheduled to receive LHRH analogues for ≥ 6 months. We assessed four domains of CP at baseline and after 6 months of ADT: 1) Working memory: Wechsler Adult Intelligence Scale III (WAIS III) Digit Span Subtest (WAIS III-Digit); 2) Visual memory: ad hoc visual memory test; 3) Visuospatial ability: Judgement of Line Orientation (JLO) and Mental Rotation of Three-Dimensional Objects (3D-Rotation); and 4) Nonverbal analytical reasoning: WAIS III Matrix Reasoning Test (WAIS III-MRT). Changes outside the baseline 95% confidence intervals were considered significant.ResultsA total of 308 patients completed the study. Of these, 245 (79.6%) experienced no statistically significant changes on any test and 63 patients (20.4%) experienced significant changes in ≥1 test. Of these, most presented a change in only one test, distributed evenly between improvements (58 patients; 18.8%) and worsening (56 patients; 18.2%). For individual tests, most patients (87.8% to 91.8%) had no change from baseline; however, the significant changes (improvement vs. deterioration, respectively) were as follows: WAIS III-Digit (6.3% vs. 5.9%); visual memory (5.3% vs. 5.7%); JLO (5.3% vs. 4.5%); 3D-Rotation (4.1% vs. 4.1%); and WAIS III-MRT (4.8% vs. 5.8%).ConclusionsCP in patients with PCa does not appear to be adversely affected by 6 months of LHRH analogue administration.

Teaser

The effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in prostate cancer (PCa) patients is not well-understood. We evaluated changes in five neuropsychological measures of CP after 6 months of ADT. Six months of ADT with LHRH analogues does not appear to significantly affect CP in patients with PCa.


http://ift.tt/2mX0hYn